<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925418</url>
  </required_header>
  <id_info>
    <org_study_id>CRYO 1/IPC 2005-007</org_study_id>
    <nct_id>NCT00925418</nct_id>
  </id_info>
  <brief_title>Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer</brief_title>
  <acronym>CRYO1</acronym>
  <official_title>Randomized Trial Evaluating the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Patient Treated for Breast or Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taxotere® can induce nails changes like dyschromia, hematoma, lines of Beau-Reil (signing the
      stop of the epithelial proliferation), abscess, or pain. In this context, this randomized,
      monocentric phase III trial evaluates the cryotherapy, using frozen glove, in the prevention
      of nails toxicity induced by Taxotere® in patient treated for breast or prostate cancer.

      Primary objective:

      Demonstrate a reduction of the nails toxicity using frozen glove during chemotherapy with
      Taxotere®.

      Secondary objectives:

      Analysis of time of protection against onycholysis Estimation of the efficiency of
      cryotherapy, and impact on quality of life Tolerance and compliance of the frozen glove
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients treated by Taxotere® with nail toxicity &gt;= 2 (CTC-AE version 3.0)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of day between inclusion and apparition of nail toxicity</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necessity of local care, existence of pains</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance and compliance for the frozen glove</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Prostate Cancer</condition>
  <condition>Nail Diseases</condition>
  <arm_group>
    <arm_group_label>Without Glove</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients do not use frozen glove during chemotherapy with Taxotere®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With Glove</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients use frozen glove during chemotherapy with Taxotere®</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Frozen Glove</intervention_name>
    <description>Using frozen glove during chemotherapy with Taxotere®</description>
    <arm_group_label>With Glove</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hormono-resistant breast cancer or metastatic prostate cancer treated by
             chemotherapy with Taxotere®.

          -  Patients aged 18 and older

          -  Nail toxicity &lt; grade 2 (CTC-AE version 3.0)

          -  Informed patients with signed consent

        Exclusion Criteria:

          -  History of treatment with taxane

          -  Raynaud syndrome

          -  Distal metastasis in superior extremity

          -  Nail diseases

          -  Distal arteriopathy

          -  Cold intolerance

          -  Peripheral neuropathy&gt;=2

          -  Pregnancy, breast feeding

          -  Unable to give informed consent

          -  Unable to have a medical follow-up for social, geographical, family or psychological
             reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole TARPIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut PAOLI-CALMETTES</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>Official web site of the sponsor</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>September 13, 2011</last_update_submitted>
  <last_update_submitted_qc>September 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm</keyword>
  <keyword>breast Neoplasm</keyword>
  <keyword>docetaxel</keyword>
  <keyword>Glove</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Nail Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

